摘要
目的检测鼻咽癌患者放化疗前、后的血清可溶性Apo-1/Fas(sApo-1/Fas)水平并探讨其临床意义。方法采用酶联免疫吸附试验法检测16例健康人及51例放、化疗前后鼻咽癌患者血清sApo-1/Fas的水平,并作分析。结果鼻咽癌患者血清sApo-1/Fas的水平高于健康对照组(P<0.01),Ⅲ期的鼻咽癌血清sApo-1/Fas的水平高于Ⅱ期(P<0.01),放化疗后原发灶及颈部肿块完全消除的鼻咽癌患者血清sApo-1/Fas水平明显低于有残留者。结论血清sApo-1/Fas可能参与鼻咽癌发生、发展过程的调控,可作为鼻咽癌患者放化疗疗效及预后观察指标。
Objective To evaluate the prognostic significance of serum soluble Apo-1/Fas levels in nasopharyngeal carcinoma patients (NPC) in pre-and post-radiotherapy and chemotherapy. Methods Enzyme linked immunosorbent assay (ELISA) was used to detect the sApo-1/Fas level in 51 cases of NPC in pre-and post-radiotherapy and chemotherapy as well as 16 normal individuals as control. Results The level of sApo-1/Fas in NPC was higher than that of control group(P<0. 01). The level of sApo-1/Fas of stage Ⅲ was higher than that of stage Ⅱ(P <0. 01). The level of sApo-1/Fas was reduced markedly in complete remission patients (P<0. 01). Conclusion sApo-1/Fas may play an important role in development and growth of NPC. It is significantly correlated with impacts on prognosis and clinical outcome.
出处
《肿瘤》
CAS
CSCD
北大核心
2005年第3期287-288,共2页
Tumor
基金
广西壮族自治区卫生厅科研基金(编号:Z200050)
关键词
鼻咽肿瘤/放射疗法
鼻咽肿瘤/药物疗法
抗原
CD95
预后
Nasopharyngeal neoplasms/radiotherapy
Nasopharyngeal neoplasms/drug therapy
Antigen,CD95
Prognosis
